Bendamustine Accord: Uses, Dosage & Side Effects
A bifunctional alkylating agent used in the treatment of chronic lymphocytic leukemia (CLL), non-Hodgkin lymphoma (NHL), and multiple myeloma
Bendamustine Accord (bendamustine hydrochloride) is an intravenous chemotherapy drug belonging to the alkylating agent class. It is used to treat several types of blood cancer, including chronic lymphocytic leukemia (CLL), non-Hodgkin lymphoma (NHL), and multiple myeloma. Bendamustine has a unique dual mechanism of action combining alkylating and antimetabolite properties, which distinguishes it from other alkylating agents. It is administered as an intravenous infusion in a hospital or clinic setting and requires a prescription. Bendamustine has become an important component of treatment regimens for hematological malignancies, offering an effective option for patients who are not candidates for other standard therapies.
Quick Facts: Bendamustine Accord
Key Takeaways
- Bendamustine Accord is a bifunctional alkylating agent with a unique dual mechanism that combines DNA alkylation with antimetabolite activity, making it effective against several blood cancers including CLL, NHL, and multiple myeloma.
- The drug is given as an intravenous infusion over 30–60 minutes on Days 1 and 2 of each treatment cycle, with cycles repeated every 3–4 weeks depending on the condition being treated.
- Bone marrow suppression (myelosuppression) is the primary dose-limiting side effect; regular blood count monitoring before, during, and between treatment cycles is essential.
- Bendamustine must not be used during pregnancy or breastfeeding; both women and men of reproductive potential must use effective contraception during and for several months after treatment.
- Vaccination with live vaccines, including yellow fever vaccine, is contraindicated during bendamustine treatment due to the risk of vaccine-strain infection from immunosuppression.
What Is Bendamustine Accord and What Is It Used For?
Bendamustine Accord contains the active substance bendamustine hydrochloride, a cytotoxic (cell-killing) medication that belongs to the class of drugs known as alkylating agents. First synthesized in the early 1960s in Germany, bendamustine was originally developed as a nitrogen mustard derivative but possesses a unique chemical structure that sets it apart from other alkylating agents. Its benzimidazole ring gives it additional properties resembling those of purine analogues (antimetabolites), resulting in a bifunctional mechanism of action that is distinct within its drug class.
The mechanism of action of bendamustine involves cross-linking DNA strands through the formation of covalent bonds with DNA bases, primarily at the N7 position of guanine. This alkylation process disrupts DNA replication and repair mechanisms, preventing cancer cells from dividing and ultimately leading to cell death (apoptosis). Unlike classical alkylating agents such as cyclophosphamide, bendamustine activates both p53-dependent and p53-independent apoptotic pathways, which helps explain its activity even in cancers that have become resistant to other alkylating agents. Additionally, the purine analogue-like activity of the benzimidazole moiety contributes to inhibition of DNA synthesis, providing a complementary cytotoxic effect.
Research has demonstrated that bendamustine induces a pattern of DNA damage and repair that is markedly different from other alkylating agents. Studies show only partial cross-resistance between bendamustine and other nitrogen mustards, which means that cancers resistant to one type of alkylating agent may still respond to bendamustine. This has made it a particularly valuable treatment option for patients whose disease has not responded to or has relapsed after prior chemotherapy.
Bendamustine Accord is approved for use as a single agent (monotherapy) or in combination with other anticancer drugs for the treatment of the following malignancies:
- Chronic lymphocytic leukemia (CLL): Bendamustine is used when combination chemotherapy with fludarabine is not suitable for the patient. CLL is the most common type of leukemia in adults, characterized by the accumulation of abnormal B-lymphocytes in the blood, bone marrow, and lymphoid tissues. Landmark clinical trials, including the CLL10 study, have established bendamustine (particularly in combination with rituximab, known as the BR regimen) as a first-line treatment option for CLL patients with significant comorbidities.
- Non-Hodgkin lymphoma (NHL): Bendamustine is indicated for indolent (slow-growing) NHL that has relapsed or not responded to previous treatment including rituximab-containing regimens. The STiL NHL 1-2003 trial demonstrated that bendamustine combined with rituximab (BR) was non-inferior and in some measures superior to the traditional R-CHOP regimen for indolent lymphomas, with a more favorable toxicity profile including less alopecia, fewer infections, and less peripheral neuropathy.
- Multiple myeloma: Bendamustine is used in combination with prednisone for the treatment of multiple myeloma when treatment with thalidomide or bortezomib is not appropriate. Multiple myeloma is a cancer of plasma cells in the bone marrow, and bendamustine provides an alternative treatment backbone for patients who cannot tolerate or have contraindications to these newer agents.
The active substance bendamustine hydrochloride is available under several brand names worldwide, including Bendamustine Accord, Bendamustine medac, Bendamustin Actavis, and Bendamustine Fresenius Kabi. All contain the same active ingredient and are used interchangeably according to physician preference and local availability. Bendamustine has been included in the World Health Organization (WHO) Model List of Essential Medicines, recognizing its importance in global oncology practice.
Unlike most alkylating agents, bendamustine combines DNA alkylation with antimetabolite-like activity from its benzimidazole ring. This dual mechanism means it can remain effective in cancers that have developed resistance to other alkylating agents, making it a valuable treatment option across multiple hematological malignancies.
What Should You Know Before Taking Bendamustine Accord?
Contraindications
There are specific circumstances in which Bendamustine Accord must not be used. These absolute contraindications must be carefully evaluated before treatment begins. Your doctor will perform a thorough assessment to ensure none of these apply to you.
- Hypersensitivity: Do not receive Bendamustine Accord if you are allergic to bendamustine hydrochloride or any of the other ingredients in the product (butylhydroxytoluene [E 321] and macrogol).
- Breastfeeding: Bendamustine Accord must not be used during breastfeeding. If treatment is necessary, breastfeeding must be discontinued before starting therapy.
- Severe hepatic impairment: Patients with severe liver damage must not receive bendamustine due to altered drug metabolism and increased risk of toxicity.
- Jaundice: If your skin or the whites of your eyes are yellow due to liver or blood problems (jaundice), bendamustine is contraindicated.
- Severe bone marrow suppression: Treatment cannot begin if your white blood cell count (leukocytes) or platelet count (thrombocytes) is severely reduced, as bendamustine would further suppress bone marrow function to dangerous levels.
- Recent major surgery: Bendamustine must not be started within 30 days of a major surgical procedure, as the drug can impair wound healing and immune function.
- Active infection: Significant infections, particularly those associated with low white blood cell counts (leukopenia), must be resolved before bendamustine treatment can begin.
- Yellow fever vaccination: Vaccination against yellow fever is absolutely contraindicated during bendamustine treatment, as the immunosuppressive effects of the drug can cause uncontrolled vaccine-strain infection.
Warnings and Precautions
PML is a rare but serious and potentially fatal brain infection that has been reported in patients treated with bendamustine. Symptoms include memory loss, difficulty thinking, difficulty walking, and vision loss. If you or anyone around you notices any of these symptoms during or after treatment, contact your doctor immediately.
Before and during treatment with Bendamustine Accord, your doctor should be informed if any of the following situations apply:
- Bone marrow suppression: If your ability to produce blood cells in the bone marrow is impaired, your white blood cell and platelet counts must be checked before each treatment cycle and between cycles. Your doctor will delay treatment if counts fall below safe levels.
- Infections: Contact your doctor immediately if you develop signs of infection such as fever, chills, cough, or other respiratory symptoms. Active infections must be treated before bendamustine can be continued.
- Skin reactions: Bendamustine can cause skin reactions that may worsen during treatment. Report any skin changes to your doctor promptly. Serious skin reactions including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) have been reported.
- Heart disease: If you have pre-existing heart conditions such as a history of heart attack, chest pain, or serious heart rhythm disturbances, inform your doctor as bendamustine may affect cardiac function.
- Tumor lysis syndrome: If you feel pain in your side, notice blood in your urine, or your urine output decreases, this may indicate tumor lysis syndrome. This occurs when cancer cells are destroyed rapidly, releasing toxic waste products that can cause kidney failure or heart problems within 48 hours of the first dose. Your doctor will ensure adequate hydration and may prescribe additional medications to prevent this complication.
- Allergic and infusion reactions: Severe allergic reactions or hypersensitivity reactions can occur. Note whether you experience any infusion-related reactions after the first treatment cycle and report these to your doctor.
- Skin cancer risk: There may be an increased risk of non-melanoma skin cancer with bendamustine use. Report any suspicious skin changes to your doctor.
Drug reaction with eosinophilia and systemic symptoms (DRESS) is a rare but potentially life-threatening adverse reaction. Symptoms include widespread rash, high body temperature, enlarged lymph nodes, and involvement of other organs. Seek immediate medical attention if these symptoms develop during bendamustine treatment.
Pregnancy and Breastfeeding
Bendamustine Accord must not be used during pregnancy unless explicitly prescribed by a doctor after careful consideration of the risks. Animal studies have shown that bendamustine can cause birth defects (teratogenicity) and damage to genetic material (genotoxicity). If bendamustine must be administered during pregnancy, the potential risks to the developing fetus should be discussed thoroughly, and genetic counseling is recommended.
Women of childbearing potential must use an effective method of contraception both before and during treatment with Bendamustine Accord. Pregnancy must be avoided during treatment and for at least 6 months after the last dose. If pregnancy occurs during treatment, contact your doctor immediately and seek genetic counseling.
Bendamustine Accord must not be used during breastfeeding. If treatment is medically necessary during the breastfeeding period, breastfeeding must be discontinued before starting therapy.
Men being treated with bendamustine should not father children during treatment and for at least 3 months after the last dose. Men are advised to seek counseling about sperm cryopreservation (freezing) before starting treatment, as there is a risk of permanent infertility.
Driving and Operating Machinery
Bendamustine Accord has a significant effect on the ability to drive and operate machinery. Do not drive or operate machines if you experience side effects such as dizziness, impaired coordination, or fatigue. You are personally responsible for assessing whether you are fit to drive or perform tasks requiring alertness. The effects and side effects of bendamustine described throughout this guide should inform your judgment. Discuss any concerns with your doctor.
How Does Bendamustine Accord Interact with Other Drugs?
Drug interactions with bendamustine primarily involve its effects on the bone marrow and immune system. Bendamustine is partially metabolized by the CYP1A2 enzyme system, and drugs that inhibit or induce this pathway may alter bendamustine levels. However, the most clinically significant interactions relate to the additive myelosuppressive and immunosuppressive effects when bendamustine is combined with other drugs that affect blood cell production or immune function.
Major Interactions
| Interacting Drug | Effect | Clinical Significance |
|---|---|---|
| Other myelosuppressive agents (e.g., other chemotherapy drugs) | Additive bone marrow suppression, increased risk of severe cytopenias | Enhanced monitoring of blood counts required; dose adjustments may be necessary |
| Live vaccines (e.g., yellow fever, MMR, varicella, BCG) | Risk of vaccine-strain infection due to immunosuppression | Absolute contraindication for yellow fever vaccine; avoid all live vaccines during and after treatment |
| Immunosuppressive agents (e.g., ciclosporin, tacrolimus) | Additive immunosuppression, increased risk of severe infections | Monitor closely for infections; consider prophylactic antimicrobials |
| CYP1A2 inhibitors (e.g., fluvoxamine, ciprofloxacin) | Potential increase in bendamustine plasma levels and active metabolite exposure | Use with caution; monitor for increased toxicity |
Minor Interactions
| Interacting Drug | Effect | Clinical Significance |
|---|---|---|
| CYP1A2 inducers (e.g., tobacco smoking, omeprazole) | Potential decrease in bendamustine plasma levels | May reduce efficacy; inform your doctor about smoking status |
| Inactivated vaccines | Reduced vaccine response due to immunosuppression | Vaccine may be less effective; discuss timing with your doctor |
| Rituximab | Intentional combination for enhanced antitumor effect in CLL and NHL | Widely used and well-studied combination (BR regimen); monitor for additive myelosuppression and infections |
| Prednisone | Used in approved combination for multiple myeloma (BP regimen) | Established combination; standard dosing protocols apply |
It is important to inform your doctor about all medications you are currently taking, including prescription and over-the-counter drugs, herbal supplements, and vitamins. Cytotoxic drugs like bendamustine may reduce the effectiveness of live virus vaccines and increase the risk of vaccine-strain infection. Inactivated vaccines may also have a diminished response. Your oncology team will advise on appropriate vaccination timing relative to your treatment schedule.
What Is the Correct Dosage of Bendamustine Accord?
Bendamustine Accord is always administered by a healthcare professional as an intravenous infusion over 30 to 60 minutes. You will be treated in a hospital or specialized clinic under the supervision of a physician experienced in cancer treatment. The dose is individually calculated based on your body surface area (BSA), which is determined from your height and weight. Your doctor will tailor the treatment to your specific condition and clinical response.
Treatment must not be started if your white blood cell count (leukocytes) and/or platelet count (thrombocytes) are below safe thresholds. These values are tested regularly throughout treatment.
Chronic Lymphocytic Leukemia (CLL)
CLL – Monotherapy
Dose: 100 mg/m² body surface area, administered intravenously on Day 1 and Day 2
Cycle length: Repeated every 4 weeks (28-day cycles)
Duration: Up to 6 cycles
Blood counts are monitored before each cycle and between cycles. Treatment is delayed if leukocyte or platelet counts fall below predetermined safe levels.
Non-Hodgkin Lymphoma (NHL)
NHL – Monotherapy or Combination Therapy
Dose: 120 mg/m² body surface area, administered intravenously on Day 1 and Day 2
Cycle length: Repeated every 3 weeks (21-day cycles)
Duration: At least 6 cycles
When combined with rituximab (the BR regimen), bendamustine is given at the same dose with rituximab administered on Day 1 of each cycle. This combination has become a standard of care for indolent NHL.
Multiple Myeloma
Multiple Myeloma – Combination with Prednisone (BP)
Bendamustine dose: 120–150 mg/m² body surface area, administered intravenously on Day 1 and Day 2
Prednisone dose: 60 mg/m² body surface area, given by injection or orally on Days 1–4
Cycle length: Repeated every 4 weeks (28-day cycles)
Duration: At least 3 cycles
Dose Adjustments
Your doctor may need to adjust your dose or delay treatment in the following situations:
- Myelosuppression: If your white blood cell or platelet counts drop below safe levels, treatment must be interrupted until counts recover. Dose reduction may be necessary for subsequent cycles.
- Hepatic impairment: Patients with moderate liver impairment require a dose reduction of approximately 30%. Bendamustine is contraindicated in severe hepatic impairment.
- Renal impairment: No dose adjustment is routinely required for patients with kidney problems. However, your doctor will assess your renal function and decide on any necessary adjustments.
- Non-hematological toxicity: Significant non-hematological side effects (such as severe infections or skin reactions) may require treatment delay or discontinuation.
Children
Bendamustine Accord is not recommended for use in children and adolescents below 18 years of age due to insufficient data on safety and efficacy in this population.
Missed Dose
If a scheduled dose of bendamustine is missed, your doctor will typically continue treatment according to the regular dosing schedule. Do not attempt to compensate for a missed dose by doubling the next one. Your oncology team will advise on the best course of action based on your individual circumstances.
Overdose
Bendamustine is administered in a controlled hospital environment, making overdose unlikely. If you are concerned about the dose you have received, speak to the doctor or nurse managing your treatment. In the event of a suspected overdose, supportive care will be provided, with particular attention to monitoring and managing bone marrow suppression, infections, and organ function.
Bendamustine Accord is always prepared and administered by trained healthcare professionals experienced in the use of cytotoxic agents. The concentrate must be diluted with 0.9% sodium chloride solution to a final volume of approximately 500 mL before infusion. Strict aseptic technique and cytotoxic handling precautions are observed throughout preparation and administration.
What Are the Side Effects of Bendamustine Accord?
Like all medicines, Bendamustine Accord can cause side effects, although not everyone will experience them. The dose-limiting toxicity of bendamustine is myelosuppression (impaired bone marrow function), which usually recovers after treatment. Reduced bone marrow function can lead to decreased blood cell counts, increasing the risk of infections, anemia, and bleeding. Your medical team will perform regular blood tests to monitor your blood counts throughout treatment.
Extravasation Warning
In very rare cases, tissue damage (necrosis) has occurred when bendamustine has accidentally leaked outside the blood vessel (extravasation) during infusion. A burning sensation at the infusion site may be a sign that the drug is being administered outside the vein. Extravasation can cause pain and slow-healing skin damage. Inform your nurse or doctor immediately if you feel any discomfort, burning, or pain at or near the infusion site.
Very Common
May affect more than 1 in 10 people
- Low white blood cell count (leukopenia) – increases susceptibility to infections
- Decreased hemoglobin (reduced oxygen-carrying capacity of the blood)
- Low platelet count (thrombocytopenia) – increases risk of bleeding
- Infections (bacterial, viral, or fungal)
- Nausea
- Vomiting
- Mucous membrane inflammation (mucositis)
- Increased blood creatinine levels (indicating kidney stress)
- Increased blood urea levels
- Fever (pyrexia)
- Fatigue
- Headache
Common
May affect up to 1 in 10 people
- Bleeding (hemorrhage)
- Tumor lysis syndrome (metabolic disturbance from rapid cancer cell death)
- Anemia (low red blood cell count, causing paleness, weakness, breathlessness)
- Low neutrophil count (neutropenia) – important for fighting infections
- Hypersensitivity reactions, including allergic dermatitis and urticaria (hives)
- Elevated liver enzymes (AST/ALT) – indicating liver stress
- Elevated alkaline phosphatase levels
- Elevated bilirubin (bile pigment) levels
- Low potassium levels (hypokalemia) – can affect heart and muscle function
- Cardiac function disturbances
- Heart rhythm disturbances (arrhythmia)
- Low or high blood pressure (hypotension or hypertension)
- Impaired lung function
- Diarrhea
- Constipation
- Mouth sores (stomatitis)
- Loss of appetite
- Hair loss (alopecia)
- Skin changes
- Absent menstruation (amenorrhea)
- Pain
- Insomnia
- Chills
- Dehydration
- Dizziness
- Itchy rash (urticaria)
Uncommon
May affect up to 1 in 100 people
- Pericardial effusion (fluid accumulation in the sac around the heart)
- Pancytopenia (impaired production of all blood cell types in the bone marrow)
- Acute leukemia (secondary malignancy)
- Heart attack (myocardial infarction), chest pain
- Heart failure
Rare
May affect up to 1 in 1,000 people
- Blood infection (sepsis)
- Severe allergic reactions (anaphylactic reactions)
- Anaphylactoid reactions (symptoms resembling anaphylaxis)
- Drowsiness
- Loss of voice (aphonia)
- Acute circulatory failure (reduced blood pressure and flow)
- Skin redness (erythema)
- Skin inflammation (dermatitis)
- Itching (pruritus)
- Macular rash (macular exanthema)
- Excessive sweating (hyperhidrosis)
- Bone marrow failure
Very Rare
May affect up to 1 in 10,000 people
- Primary atypical pneumonia
- Hemolysis (destruction of red blood cells)
- Anaphylactic shock (rapid blood pressure drop with skin reactions)
- Altered taste sensation (dysgeusia)
- Tingling or numbness (paresthesia)
- Discomfort and pain in arms or legs (peripheral neuropathy)
- Autonomic nervous system disturbances
- Brain inflammation (encephalitis)
- Coordination difficulties (ataxia)
- Increased heart rate (tachycardia)
- Vein inflammation (phlebitis)
- Lung fibrosis (scarring of lung tissue)
- Hemorrhagic esophagitis (bleeding and inflammation of the esophagus)
- Gastrointestinal bleeding
- Infertility
- Multiple organ failure
Not Known
Frequency cannot be estimated from available data
- Kidney failure
- Liver failure
- Atrial fibrillation (irregular and often rapid heart rhythm)
- Stevens-Johnson syndrome / toxic epidermal necrolysis (severe skin reactions with blistering and peeling)
- Drug reaction with eosinophilia and systemic symptoms (DRESS syndrome)
- Rash when combined with rituximab
- Pneumonitis (lung inflammation)
- Pulmonary hemorrhage (bleeding from the lungs)
- Nephrogenic diabetes insipidus (excessive urination and thirst)
- Secondary tumors (myelodysplastic syndrome, acute myeloid leukemia, bronchial carcinoma) reported after bendamustine treatment
Contact your doctor or seek emergency care immediately if you experience: severe skin rash with redness, blisters, and peeling (signs of SJS/TEN); widespread rash with high fever and enlarged lymph nodes (signs of DRESS syndrome); sudden chest pain or difficulty breathing; signs of severe infection such as high fever with shaking chills; or severe bleeding.
If you experience any side effects, including those not listed here, tell your doctor or nurse. You can also report suspected side effects to your national pharmacovigilance authority (e.g., the EMA in Europe, the FDA MedWatch program in the United States, or the MHRA Yellow Card Scheme in the United Kingdom) to support ongoing safety monitoring of bendamustine.
How Should Bendamustine Accord Be Stored?
Keep this medicine out of the sight and reach of children. Do not use after the expiry date stated on the label and outer carton after EXP. The expiry date refers to the last day of that month.
- Unopened vials: Store and transport in a refrigerator at 2°C to 8°C (36°F to 46°F). Do not freeze.
- After opening: Chemical, physical, and microbiological stability has been demonstrated for 28 days at 2–8°C. After opening, the concentrate may be stored for up to 28 days at 2–8°C.
- After dilution (infusion solution): The diluted solution is stable for 3.5 hours at 25°C and for 2 days at 2–8°C in polyethylene bags. From a microbiological standpoint, the diluted solution should be used immediately.
- Multi-dose vials: Record the date and time of first withdrawal on the vial label. Between uses, do not re-equilibrate the solution with water for injection or other diluents. Return the multi-dose vial to storage at 2–8°C between uses.
- Inspection: Do not use if you observe visible particles in the solution or if the solution is not clear, colorless to yellow.
As Bendamustine Accord is prepared and administered in a hospital or clinic, storage will be handled by your healthcare team and pharmacy. Unused medicine and waste material should be disposed of according to local guidelines for cytotoxic waste to protect the environment.
What Does Bendamustine Accord Contain?
Active Substance
The active substance is bendamustine hydrochloride (as monohydrate). Each milliliter of concentrate for solution for infusion contains 25 mg of bendamustine hydrochloride. The product is available in two vial sizes:
- 1 mL vial: Contains 25 mg bendamustine hydrochloride (as monohydrate)
- 4 mL vial: Contains 100 mg bendamustine hydrochloride (as monohydrate)
Inactive Ingredients (Excipients)
- Butylhydroxytoluene (BHT, E 321): An antioxidant used to preserve the stability of the concentrate
- Macrogol (polyethylene glycol): A solubilizing agent used to maintain the drug in solution
Appearance and Packaging
Bendamustine Accord is a clear, colorless to yellow solution in amber glass vials with chlorobutyl rubber stoppers. The 1 mL vial has a red, smooth, tear-off plastic cap with aluminum seal. The 4 mL vial has a white, smooth, tear-off plastic cap with red aluminum seal. The vials are enclosed in a protective sleeve. Bendamustine Accord is available in packs containing 1 or 5 vials. Not all pack sizes may be marketed in every country.
Manufacturer
The marketing authorization holder is Accord Healthcare B.V. (Utrecht, Netherlands). The product is manufactured by Accord Healthcare Polska Sp.z o.o. (Pabianice, Poland) and Accord Healthcare Single Member S.A. (Schimatari, Greece).
Frequently Asked Questions About Bendamustine Accord
Bendamustine Accord, Bendamustine medac, Bendamustin Actavis, and Bendamustine Fresenius Kabi all contain the same active substance (bendamustine hydrochloride) at the same concentration. They are therapeutically equivalent and approved for the same indications. The choice between brands typically depends on hospital procurement contracts and local availability. Minor differences may exist in excipients (inactive ingredients) and packaging, but the clinical effects are the same.
The duration of treatment depends on the condition being treated and your response to therapy. For CLL, treatment typically involves up to 6 cycles given every 4 weeks (approximately 6 months). For NHL, at least 6 cycles are given every 3 weeks (approximately 4–5 months). For multiple myeloma, at least 3 cycles are given every 4 weeks. Your doctor may extend or shorten treatment based on how well the cancer responds and how well you tolerate the medication. There are no fixed time limits – the treating physician will determine the optimal duration for your individual case.
Live vaccines (such as yellow fever, MMR, varicella, and BCG) are contraindicated during bendamustine treatment due to the risk of developing a serious infection from the vaccine virus itself. Inactivated (killed) vaccines may be given but may produce a weaker immune response than normal. It is important to discuss your vaccination schedule with your oncology team. Ideally, any needed vaccinations should be completed well before starting chemotherapy. Your doctor will advise on when it is safe to resume vaccinations after completing treatment.
Regular blood tests are essential during bendamustine treatment. Before each treatment cycle, your doctor will check your complete blood count (CBC), including white blood cells (leukocytes), neutrophils, platelets (thrombocytes), and hemoglobin (red blood cells). Blood counts are also monitored between cycles. Additionally, liver function tests (AST, ALT, alkaline phosphatase, bilirubin), kidney function tests (creatinine, urea), and electrolyte levels (especially potassium) will be checked regularly. These tests help your doctor detect potential toxicity early and make dose adjustments as needed.
Hair loss (alopecia) is listed as a common side effect of bendamustine, occurring in up to 1 in 10 patients. However, compared to many other chemotherapy regimens (such as R-CHOP), the degree of hair loss with bendamustine is generally less severe. Many patients experience hair thinning rather than complete hair loss. This was one of the advantages noted in the STiL study comparing bendamustine-rituximab (BR) to R-CHOP for indolent NHL. Hair typically regrows after treatment is completed.
Yes, bendamustine can affect fertility in both men and women. In women, absence of menstruation (amenorrhea) is a common side effect, and permanent infertility is possible. In men, bendamustine can damage sperm production, and there is a risk of permanent infertility. Male patients are strongly advised to seek counseling about sperm cryopreservation (freezing and storing sperm) before starting treatment. Men should avoid fathering children during treatment and for at least 3 months after the last dose. Women should avoid becoming pregnant during treatment and for at least 6 months afterward.
References
- European Medicines Agency (EMA). Bendamustine hydrochloride – Summary of Product Characteristics. EMA/CHMP. Last updated 2025.
- Rummel MJ, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial (STiL NHL 1-2003). Lancet. 2013;381(9873):1203-1210.
- Eichhorst B, Fink AM, Bahlo J, et al. First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial. Lancet Oncol. 2016;17(7):928-942.
- Flinn IW, van der Jagt R, Kahl BS, et al. Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study. Blood. 2014;123(19):2944-2952.
- National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. Version 1.2025.
- National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: B-Cell Lymphomas. Version 2.2025.
- European Society for Medical Oncology (ESMO). Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2024.
- World Health Organization (WHO). Model List of Essential Medicines, 23rd Edition. Geneva: WHO; 2023.
- Cheson BD, Brugger W, Damaj GL, et al. Optimal use of bendamustine in hematologic disorders: Treatment recommendations from an international consensus panel – an update. Leuk Lymphoma. 2016;57(4):766-782.
- Dreyling M, Ghielmini M, Rule S, et al. Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2021;32(3):298-308.
Editorial Team
Medical Content Team
Specialist physicians in oncology, hematology, and clinical pharmacology with extensive experience in chemotherapy protocols and blood cancer management.
Medical Review Board
Independent panel of board-certified oncologists and hematologists who verify clinical accuracy against current EMA, FDA, NCCN, and ESMO guidelines.
Pharmacology Editors
Clinical pharmacologists specializing in oncology drug interactions, pharmacokinetics, and evidence-based prescribing information.
Accessibility Team
Specialists in digital accessibility ensuring WCAG 2.2 Level AAA compliance and screen reader compatibility for all medical content.
All content follows the GRADE evidence framework and is reviewed against international treatment guidelines. Our editorial process ensures independence from pharmaceutical industry influence. For questions about our editorial standards, visit our Editorial Standards page.